Study says DPP-IV benefits may go beyond diabetes

Share this article:

DPP-IV diabetes medications may have benefits beyond insulin control. PharmaTimes reports that a Brigham and Women's Hospital study shows the medications may be associated with a reduced risk of autoimmune diseases among type-2 diabetics. PT says researcher Seoyoung Kim told reporters at the American College of Rheumatology conference that diabetics taking DPP-IV combination therapy were 34% less likely to develop RA and reduced their risk of other autoimmune diseases by 27%.

PT notes that the study is not definitive, but further evidence would benefit Merck's Januvia (which has seen sales slide) and the Boehringer Ingelheim/Eli Lilly drug Tradjenta. The DPP-IV class also includes the Bristol-Myers Squibb/AstraZeneca drug Onglyza.

The diabetes category as a whole is getting tighter. Merck noted in its conference call, for example, that "the DPP-IV market and branded worldwide diabetic market isn't growing." Additional pressures, such as being squeezed out of PBM formulary offerings have added to category pressures.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.